FORMULATION, OPTIMIZATION, AND IN VITRO CHARACTERIZATION OF DASATINIB LOADED POLYMERIC NANOCARRIERS TO EXTEND THE RELEASE OF THE MODEL DRUG
DOI:
https://doi.org/10.22159/ijap.2021v13i5.41995Keywords:
Quality by design, Gold nanoparticles, Dasatinib, Full factorial design, Sustained releaseAbstract
Objective: The present research aims to design, develop, optimize, characterize and evaluate dasatinib (DSB) loaded polymeric nanocarriers to treat chronic myeloid leukaemia (CML) by adopting a quality by design (QbD) approach.
Methods: Risk assessment was performed by using failure modes and effects analysis, and optimization of nanoformulation was done by adopting 23 full factorial design. The optimized nanoformulation was characterized by different characterization techniques and evaluated by various in vitro studies.
Results: Surface morphology and shape were found to be smooth and spherical. Stability study results revealed that the nanoformulation could be stored in all three storage conditions for safe and long-term use since it retained its pharmaceutical properties. Drug release was 32.06 % in the first 4 h and 79.34 % by the end of 48 h which infers a sustained-release pattern. The hemocompatibility results showed no sign of hemolysis. Cellular uptake study showed approximately 10 to 20-fold much higher intracellular fluorescence intensities of nanoformulation than DSB. Cytotoxicity results confirmed that when compared to the pure drug, the optimized nanoformulation have a potential cytotoxic effect in the treatment of CML since it exhibited a significantly more % growth inhibition. Cell apoptosis assay revealed that the nanoformulation could provide significant antileukaemia activity against K562 cells and further induce K562 cell death with a dose and time-dependent manner.
Conclusion: The results of the characterization and evaluation studies showed that the developed nanoformulation offered significant advantages, making it a potential delivery system of DSB for more effective treatment of CML.
Downloads
References
Mian AA, Rafiei A, Haberbosch I, Zeifman A, Titov I, Stroylov V, et al. PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation. Leukemia 2015;29:1104-14.
Obr A, Roselova P, Grebenova D, Kuzelova K. Real-time analysis of imatinib-and dasatinib-induced effects on chronic myelogenous leukemia cell interaction with fibronectin. PloS One 2014;9:e107367.
Steinberg M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther 2007;29:2289-308.
Latagliata R, Breccia M, Fava C, Stagno F, Tiribelli M, Luciano L, et al. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. Hematol Oncol 2013;31:103-9.
Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 2014;66:2-5.
Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010;7:653.
Muddineti OS, Ghosh B, Biswas S. Current trends in using polymer-coated gold nanoparticles for cancer therapy. Int J Pharm 2015;484:252-67.
Cobley CM, Chen J, Cho EC, Wang LV, Xia Y. Gold nanostructures: a class of multifunctional materials for biomedical applications. Chem Soc Rev 2011;40:44-56.
Dreaden EC, Mackey MA, Huang X, Kang B, El-Sayed MA. Beating cancer in multiple ways using nanogold. Chem Soc Rev 2011;40:3391-404.
Kumar A, Zhang X, Liang XJ. Gold nanoparticles: emerging paradigm for targeted drug delivery system. Biotechnol Adv 2013;31:593-606.
Vigderman L, Zubarev ER. Therapeutic platforms based on gold nanoparticles and their covalent conjugates with drug molecules. Adv Drug Delivery Rev 2013;65:663-76.
Birla SS, Tiwari VV, Gade AK, Ingle AP, Yadav AP, Rai MK. Fabrication of silver nanoparticles by Phoma glomerata and its combined effect against Escherichia coli, pseudomonas aeruginosa and staphylococcus aureus. Lett Appl Microbiol 2009;48:173-9.
Rai M, Yadav A, Gade A. CRC 675-current trends in phytosynthesis of metal nanoparticles. Crit Rev Biotechnol 2008;28:277-84.
Singh P, Kim YJ, Zhang D, Yang DC. Biological synthesis of nanoparticles from plants and microorganisms. Trends Biotechnol 2016;34:588-99.
Xue M, Hu S, Lu Y, Zhang Y, Jiang X, An S, et al. Development of chitosan nanoparticles as drug delivery system for a prototype capsid inhibitor. Int J Pharm 2015;495:771-82.
Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro-and nanoparticles in drug delivery. J Controlled Release 2004;100:5-28.
Boisselier E, Astruc D. Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. Chem Soc Rev 2009;38:1759-82.
Ehlerding EB, Chen F, Cai W. Biodegradable and renal clearable inorganic nanoparticles. Adv Sci 2016;3:1500223.
Sharma S, Parmar A, Kori S, Sandhir R. PLGA-based nanoparticles: a new paradigm in biomedical applications. Trends Anal Chem 2016;80:30-40.
Dhat S, Pund S, Kokare C, Sharma P, Shrivastava B. Risk management and statistical multivariate analysis approach for design and optimization of satranidazole nanoparticles. Eur J Pharm Sci 2017;96:273-83.
Garg NK, Sharma G, Singh B, Nirbhavane P, Tyagi RK, Shukla R, et al. Quality by Design (QbD)-enabled development of aceclofenac loaded-nano structured lipid carriers (NLCs): an improved dermatokinetic profile for the inflammatory disorder (s). Int J Pharm 2017;517:413-31.
Lawrence XY, Amidon G, Khan MA, Hoag SW, Polli J, Raju GK, et al. Understanding pharmaceutical quality by design. AAPS J 2014;16:771-83.
Sangshetti JN, Deshpande M, Zaheer Z, Shinde DB, Arote R. Quality by design approach: regulatory need. Arab J Chem 2017;10:S3412-25.
Upadhyay M, Adena SK, Vardhan H, Pandey S, Mishra B. Development and optimization of locust bean gum and sodium alginate interpenetrating polymeric network of capecitabine. Drug Dev Ind Pharm 2018;44:511-21.
Clogston JD, Patri AK. Zeta potential measurement. In: Scott E, McNeil. editor. Characterization of nanoparticles intended for drug delivery. 1st ed. New Jersey: Humana Press; 2011. p. 63-70.
Govender T, Stolnik S, Garnett MC, Illum L, Davis SS. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water-soluble drug. J Controlled Release 1999;57:171-85.
Upadhyay M, Adena SK, Vardhan H, Yadav SK, Mishra B. Locust bean gum and sodium alginate-based interpenetrating polymeric network microbeads encapsulating capecitabine: improved pharmacokinetics, cytotoxicity and in vivo antitumor activity. Mater Sci Eng C 2019;104:109958.
Vardhan H, Mittal P, Adena SK, Upadhyay M, Mishra B. Development of long-circulating docetaxel loaded poly (3-hydroxybutyrate-co-3-hydroxyvalerate) nanoparticles: optimization, pharmacokinetic, cytotoxicity and in vivo assessments. Int J Biol Macromol 2017;103:791-801.
Soshnikova V, Kim YJ, Singh P, Huo Y, Markus J, Ahn S, et al. Cardamom fruits as a green resource for facile synthesis of gold and silver nanoparticles and their biological applications. Artif Cells Nanomed Biotechnol 2018;46:108-17.
Engelbrekt C, SØrensen KH, Zhang J, Welinder AC, Jensen PS, Ulstrup J. Green synthesis of gold nanoparticles with starch–glucose and application in bioelectrochemistry. J Mater Chem 2009;19:7839-47.
Rao K, Imran M, Jabri T, Ali I, Perveen S, Ahmed S, et al. Gum tragacanth stabilized green gold nanoparticles as cargos for naringin loading: a morphological investigation through AFM. Carbohydr Polym 2017;174:243-52.
Vardhan H, Mittal P, Adena SK, Mishra B. Long-circulating polyhydroxybutyrate-co-hydroxyvalerate nanoparticles for tumor-targeted docetaxel delivery: formulation, optimization and in vitro characterization. Eur J Pharm Sci 2017;99:85-94.
Soni N, Soni N, Pandey H, Maheshwari R, Kesharwani P, Tekade RK. Augmented delivery of gemcitabine in lung cancer cells exploring mannose anchored solid lipid nanoparticles. J Colloid Interface Sci 2016;481:107-16.
Adena SK, Upadhyay M, Vardhan H, Mishra B. Development, optimization, and in vitro characterization of dasatinib-loaded PEG functionalized chitosan capped gold nanoparticles using Box-Behnken experimental design. Drug Dev Ind Pharm 2018;44:493-501.
Peppas NA. Analysis of fickian and non-fickian drug release from polymers. Pharm Acta Helv 1985;60:110-1.
Fornaguera C, Caldero G, Mitjans M, Vinardell MP, Solans C, Vauthier C. Interactions of PLGA nanoparticles with blood components: protein adsorption, coagulation, activation of the complement system and hemolysis studies. Nanoscale 2015;7:6045-58.
Alkilany AM, Murphy CJ. Toxicity and cellular uptake of gold nanoparticles: what we have learned so far? J Nanopart Res 2010;12:2313-33.
Vardhan H, Mittal P, Adena SK, Upadhyay M, Yadav SK, Mishra B. Process optimization and in vivo performance of docetaxel loaded PHBV-TPGS therapeutic vesicles: a synergistic approach. Int J Biol Macromol 2018;108:729-43.
Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006;1:1112.
Rieger AM, Nelson KL, Konowalchuk JD, Barreda DR. Modified annexin V/propidium iodide apoptosis assay for accurate assessment of cell death. J Vis Exp 2011;50:2597.
Pund S, Shete Y, Jagadale S. Multivariate analysis of physicochemical characteristics of lipid-based nanoemulsifying cilostazol-quality by design. Colloids Surf B 2014;115:29-36.
Bhokare SG, Marathe RP. Rosuvastatin calcium loaded chitosan nanoparticles: preparation evaluation and in vitro release studies. Int J Appl Pharm 2020;7:95-102.
Viswanadh MK, Vikas, Jha A, Reddy Adena SK, Mehata AK, Priya V, et al. Formulation and in vivo efficacy study of cetuximab decorated targeted bioadhesive nanomedicine for non-small-cell lung cancer therapy. Nanomedicine 2020;15:2345-67.
Tahir K, Nazir S, Li B, Khan AU, Khan ZU, Gong PY, et al. Nerium oleander leaves extract mediated synthesis of gold nanoparticles and its antioxidant activity. Mater Lett 2015;156:198-201.
Pertiwi RD, Suwaldi EP, Martien R. Bio-nanoparticles: green synthesis of gold nanoparticles and assessment of biological evaluation. Int J Appl Pharm 2019;11:133-8.
Devi L, Gupta R, Jain SK, Singh S, Kesharwani P. Synthesis, characterization and in vitro assessment of colloidal gold nanoparticles of Gemcitabine with natural polysaccharides for treatment of breast cancer. J Drug Delivery 2020;56:101565.
Rao K, Imran M, Jabri T, Ali I, Perveen S, Ahmed S, et al. Gum tragacanth stabilized green gold nanoparticles as cargos for naringin loading: a morphological investigation through AFM. Carbohydr Polym 2017;174:243-52.
Niza E, Noblejas Lopez MD, Bravo I, Nieto Jimenez C, Castro Osma JA, Canales Vazquez J, et al. Trastuzumab-targeted biodegradable nanoparticles for enhanced delivery of dasatinib in HER2+metastasic breast cancer. Nanomaterials 2019;9:1793.
Chen X, Hu Z, Zhou L, Zhang F, Wan J, Wang H. Self-assembling a natural small molecular inhibitor that shows aggregation-induced emission and potentiates antitumor efficacy. Nanoscale Horiz 2020;6:33-42.
Mandal S, Bakeine GJ, Krol S, Ferrari C, Clerici AM, Zonta C, et al. Design, development and characterization of multi-functionalized gold nanoparticles for biodetection and targeted boron delivery in BNCT applications. Appl Radiat Isot 2011;69:1692-7.
Thapliyal A, Chandra A. Antibacterial and anticancer potential of silver nanoparticles synthesized using gallic acid in bentonite/starch bio-nano composites. Int J Appl Pharm 2018;10:178-89.
Derbala SA, Elkady ME, Elbanhawy RA, AF AA. Antiproliferative and antioxidant effects of eruca sativa (jarjeer) leaves extract on carcinoma of women’s breast. Asian J Pharm Clin Res 2021;9:89-92.
Published
How to Cite
Issue
Section
Copyright (c) 2021 Sandeep Kumar Reddy Adena, KASI VISWANADH MATTE , RAMOJI KOSURU
This work is licensed under a Creative Commons Attribution 4.0 International License.